Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Non-Current Deferred Tax Liability (2020 - 2025)

Bioventus' Non-Current Deferred Tax Liability history spans 6 years, with the latest figure at $433000.0 for Q4 2025.

  • For Q4 2025, Non-Current Deferred Tax Liability fell 23.23% year-over-year to $433000.0; the TTM value through Dec 2025 reached $433000.0, down 23.23%, while the annual FY2025 figure was $433000.0, 23.23% down from the prior year.
  • Non-Current Deferred Tax Liability reached $433000.0 in Q4 2025 per BVS's latest filing, down from $786000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $159.3 million in Q4 2022 to a low of $351000.0 in Q2 2023.
  • Average Non-Current Deferred Tax Liability over 5 years is $36.7 million, with a median of $1.8 million recorded in 2022.
  • Peak YoY movement for Non-Current Deferred Tax Liability: soared 1674.27% in 2021, then crashed 99.7% in 2023.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $59.7 million in 2021, then crashed by 96.23% to $2.2 million in 2022, then plummeted by 46.04% to $1.2 million in 2023, then plummeted by 53.5% to $564000.0 in 2024, then decreased by 23.23% to $433000.0 in 2025.
  • Per Business Quant, the three most recent readings for BVS's Non-Current Deferred Tax Liability are $433000.0 (Q4 2025), $786000.0 (Q3 2025), and $651000.0 (Q2 2025).